Healthcare Industry News:  NEXAVAR 

Biopharmaceuticals Personnel

 News Release - June 1, 2006

ZIOPHARM Appoints Brian Schwartz, M.D. as Chief Medical Officer

Key Physician Responsible for the Global Clinical Development of Sorafenib (NEXAVAR(R))

NEW YORK--(HSMN NewsFeed)--June 1, 2006--ZIOPHARM Oncology, Inc. (OTC BB: ZIOP ) announced today the appointment of Brian Schwartz, M.D., as Senior Vice President for Medical and Regulatory Affairs and Chief Medical Officer. Dr. Schwartz will work directly with Chief Executive Officer Jonathan Lewis, M.D., Ph.D., on corporate strategy and with Dick Bagley, President and Chief Operating Officer, for operational activities.

Dr. Schwartz joins ZIOPHARM with impressive drug development registration experience from the pharmaceutical industry with both Bayer Healthcare and Leo Laboratories. Over the last six years, Brian has focused on oncology clinical development of novel cytostatic, cytotoxic and immunological agents, achieving Awards for Excellence from both employers. At Bayer, Dr. Schwartz was the key physician responsible for the global clinical development of sorafenib (NEXAVAR) and led the clinical team through a successful phase III trial in renal cell cancer, leading to Food and Drug Administration (FDA) approval on December 20, 2005. Brian has extensive regulatory experience in working with the U.S. Food and Drug Administration Oncology Division, the European Medicines Evaluation Agency, (EMEA) and numerous other health authorities. Most recently, Brian was responsible for U.S. clinical and regulatory activities including phase IV studies and interactions with the National Cancer Institute and other oncology cooperative groups. Brian has extensive experience in working with Scientific Advisory Boards, international project teams, and in leading joint development projects with biotechnology companies. Dr. Schwartz received an M.D. degree in Pretoria, South Africa and was at the University of Toronto before joining Leo Laboratories Canada.

"Dr. Schwartz's outstanding hands-on, but enabling leadership style in the development and registration of the oncology drug sorafenib worldwide is highly recognized in the medical community, and will complement the strong development team we have built at ZIOPHARM," said Jon Lewis, CEO. "Brian will serve as a key member of our management team, and his extensive experience, success and ambition for better and safer treatments for cancer will be invaluable as we further develop ZIO-101, ZIO-201, and new product candidates."

"ZIOPHARM is dedicated to extending the lives of patients with cancer by developing potential treatment options that are safer and more effective," said Dr. Schwartz. "I am absolutely thrilled to join the team at ZIOPHARM and look forward to helping the Company complete the development process for its lead product candidates and to bring important cancer therapies to patients who greatly need them."

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Source: ZIOPHARM Oncology

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.